ARVN — ARVINAS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1655759 ·
Last close
$8.27
Market Cap
$533.59M
52W High
$11.40
52W Low
$6.97
ADV30
797,027
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 15,600,000 | — | -63,800,000 | -57,600,000 | 647,500,000 | 87,300,000 | 260,700,000 |
| Dec 2025 | 9,500,000 | — | -74,600,000 | -67,400,000 | 717,900,000 | 142,900,000 | 284,100,000 |
| Sep 2025 | 41,900,000 | — | -43,800,000 | -35,100,000 | 844,300,000 | 101,500,000 | 279,900,000 |
| Jun 2025 | 22,400,000 | — | -71,500,000 | -61,200,000 | 909,300,000 | 114,900,000 | 300,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-254,100,000
Investing CF
$351,800,000
Financing CF
$-91,400,000
CapEx
$-2,800,000
Dividends Paid
—
Buybacks
$-74,100,000
EPS Diluted TTM
$-3.32
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,612,400,000
Inventory
—
Receivables
$6,400,000
ST Investments
$542,500,000
EBIT TTM
$-118,500,000
Pretax Income TTM
$-80,400,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$89,400,000
EBITDA
$-246,500,000
Free Cash Flow
$-199,637,504
Enterprise Value
$-55,488,968
Total Cash
$614,899,968
Total Debt
$8,400,000
Shares Out
64,521,198
Trailing EPS
$-3.18
Book Value
$6.00
ROE
-42.3%
ROA
-18.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 262,600,000 | -118,500,000 | -80,800,000 | 717,900,000 | 284,100,000 | — | -273,800,000 |
| Dec 2024 | 263,400,000 | -250,200,000 | -198,900,000 | 1,091,400,000 | 529,800,000 | — | -259,300,000 |
| Dec 2023 | 78,500,000 | -401,500,000 | -367,300,000 | 1,304,600,000 | 644,600,000 | — | -347,800,000 |
| Dec 2022 | 131,400,000 | -263,200,000 | -282,500,000 | 1,268,800,000 | 703,900,000 | — | -273,500,000 |
TTM Snapshot
Revenues TTM
$153,600,000
NetIncome TTM
$-212,200,000
OpCashFlow TTM
$0
Assets (Latest)
$1,091,400,000
Forward EPS
$-3.45
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $542.99M | $27.40 | — |
| AQST | Aquestive Therapeutics, Inc. | $516.92M | $4.12 | — |
| CTNM | Contineum Therapeutics, Inc. | $497.08M | $15.19 | — |
| NVCT | Nuvectis Pharma, Inc. | $578.49M | $18.35 | — |
| ANL | Adlai Nortye Ltd. | $579.71M | $9.87 | — |
News headlines (Yahoo Finance, 1h cache)
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
2026-06-18 11:30 · Yahoo
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
2026-06-16 20:01 · Yahoo
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
2026-06-12 12:25 · Yahoo
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
2026-06-05 16:10 · Yahoo
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
2026-06-04 12:00 · Yahoo
Arvinas to Present at Jefferies Global Healthcare Conference
2026-05-29 20:01 · Yahoo
Arvinas Employees Give Back During Company-wide Impact Day
2026-05-18 14:30 · Yahoo
Bullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
2026-05-16 13:40 · Yahoo
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
2026-05-15 20:31 · Yahoo
Earnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
2026-05-14 12:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.